1 hr 6 min

David H. Ilson, MD, PhD - Up Close and Personalizing Gastric Cancer Care: Precision Medicine With HER2-Targeted Therapies and Other Novel Agents PeerView Internal Medicine CME/CNE/CPE Audio Podcast

    • Science

Go online to PeerView.com/JQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The ability to personalize treatment for patients with gastric cancer has grown along with the improved understanding of the biologic rationale for therapeutic targeting. In this activity, based on a recent live webcast, an expert panel provides the latest efficacy and safety data for established and emerging therapeutics for gastric cancer including HER2-directed antibody–drug conjugates and addresses practical strategies for choosing treatments based on treatment history, patient preference, performance status, and biomarker status for patients with advanced gastric cancer. Upon completion of this activity, participants should be better able to: Describe the biologic rationale for therapeutic targeting of gastric cancer, such as HER2 or PD-L1 overexpression, Summarize expert and guideline-based recommendations to accurately test for biomarkers in gastric cancer that can guide appropriate treatment selection, Appraise the latest safety and efficacy data of established and emerging therapeutics for gastric cancer, such as checkpoint inhibitors, novel cytotoxic agents, and HER2-directed antibody-drug conjugates, Select appropriate validated or emerging therapeutic strategies for advanced gastric/GEJ cancers based on treatment history, patient preference, performance status, and biomarker status for patients who have progressed following first-line treatment.

Go online to PeerView.com/JQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The ability to personalize treatment for patients with gastric cancer has grown along with the improved understanding of the biologic rationale for therapeutic targeting. In this activity, based on a recent live webcast, an expert panel provides the latest efficacy and safety data for established and emerging therapeutics for gastric cancer including HER2-directed antibody–drug conjugates and addresses practical strategies for choosing treatments based on treatment history, patient preference, performance status, and biomarker status for patients with advanced gastric cancer. Upon completion of this activity, participants should be better able to: Describe the biologic rationale for therapeutic targeting of gastric cancer, such as HER2 or PD-L1 overexpression, Summarize expert and guideline-based recommendations to accurately test for biomarkers in gastric cancer that can guide appropriate treatment selection, Appraise the latest safety and efficacy data of established and emerging therapeutics for gastric cancer, such as checkpoint inhibitors, novel cytotoxic agents, and HER2-directed antibody-drug conjugates, Select appropriate validated or emerging therapeutic strategies for advanced gastric/GEJ cancers based on treatment history, patient preference, performance status, and biomarker status for patients who have progressed following first-line treatment.

1 hr 6 min

Top Podcasts In Science

More by PeerView Press